Related Articles
Expression of UCP2 is associated with sensitivity to platinum‑based chemotherapy for ovarian serous carcinoma
PRMT1 expression predicts sensitivity to platinum‑based chemotherapy in patients with ovarian serous carcinoma
T‑box 2 expression is a useful indicator of the response to neoadjuvant chemotherapy for patients with locally advanced uterine cervical squamous cell carcinoma
Real‑time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin
The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer